Home › Research › Brain scans and imaging
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S et al.. EBioMedicine, 2022-02-06
Topic: Brain proteins, microglia and lab models
Background Tau in Alzheimer's disease (AD) is assessed via cerebrospinal fluid (CSF) and Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in blood have been recently developed. We aim to investigate agreement of tau status as determined by [ 18 F]MK6240 tau-PET, plasma pTau181 and pTau231. Methods We assessed cognitively unimpaired young, cognitively unimpaired, mild cognitive impairment and AD individuals with [ 18 F]MK6240, plasma pTau181, pTau 231, [ 18 F]AZD4694 amyloid-PET and MRI. A subset underwent CSF assessment. We conducted ROC curves to obtain cut-off values for plasma pTau epitopes. Individuals were categorized as positive or negative in all biomarkers. We then compared the distribution among concordant and discordant groups in relation to diagnosis, Aβ status, APOEε4 status, [ 18 F]AZD4694 global SUVR, hippocampal volume and CSF pTau181. Findings The threshold for positivity was 15.085 pg/mL for plasma pTau181 and 17.652 pg/mL for plasma pTau231. Most individuals had concordant statuses, however, 18% of plasma181/PET, 26% of plasma231/PET and 25% of the pTau231/pTau181 were discordant. Positivity to at least one biomarker was often accompanied by diagnosis of cognitive impairment, Aβ positivity, APOEε4 carriership, higher levels of [ 18 F]AZD4694 global SUVR, hippocampal atrophy and CSF pTau181. Interpretation Plasma pTau181, pTau231 and [ 18 F]MK6240 seem to reflect different stages of tau progression. Plasma biomarkers can be useful in the context of diagnostic information and clinical trials, to evaluate the disease stage. Moreover, they seem to confidently evaluate tau-PET positivity. Funding Moreover, this study was supported by Weston Brain Institute, Canadian Institute of Health Research and Fonds de Recherche du Québec.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tissot, C., Therriault, J., Kunach, P., L Benedet, A., Pascoal, T. A., Ashton, N. J., et al. (2022). Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine. https://doi.org/10.1016/j.ebiom.2022.103837
Vancouver
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, et al. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine. 2022. doi:10.1016/j.ebiom.2022.103837. PMID: 35134647.
BibTeX
@article{tissot2022-35134647,
author = {Tissot, C. and Therriault, J. and Kunach, P. and L Benedet, A. and Pascoal, T. A. and Ashton, N. J. and Karikari, T. K. and Servaes, S. and others},
title = {{Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET}},
journal = {EBioMedicine},
year = {2022},
doi = {10.1016/j.ebiom.2022.103837},
pmid = {35134647},
url = {https://doi.org/10.1016/j.ebiom.2022.103837}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Positivity to at least one biomarker was often accompanied by diagnosis of cognitive impairment, Aβ positivity, APOEε4 carriership, higher levels of [ 18 F]AZD4694 global SUVR, hippocampal atrophy and CSF pTau181.
- Interpretation Plasma pTau181, pTau231 and [ 18 F]MK6240 seem to reflect different stages of tau progression.
- Plasma biomarkers can be useful in the context of diagnostic information and clinical trials, to evaluate the disease stage.
- Moreover, they seem to confidently evaluate tau-PET positivity.
- Funding Moreover, this study was supported by Weston Brain Institute, Canadian Institute of Health Research and Fonds de Recherche du Québec.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (EBioMedicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35134647) |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Brain scans and imaging
Also tagged “determined”
3 studies in the library carry the topic tag “determined”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.